Inhibrx Biosciences (INBX) Study update summary

Study population and background

• 45 evaluable patients with advanced or metastatic unresectable colorectal cancer were enrolled, with 70% receiving ozekibart plus FOLFIRI as fourth-line therapy and 30% as third-line therapy.

• 80% of patients were refractory to irinotecan prior to study entry.

• 68% of patients had liver metastasis, a common and challenging feature in CRC.

Study design

• Phase 1/2 study evaluated ozekibart (INBRX-109) with FOLFIRI in advanced or metastatic, unresectable colorectal cancer patients.

Efficacy results

• Observed objective response rate (ORR) was 20% per RECIST v1.1, a significant improvement over the near-zero ORR of standard care in this setting.

• Nearly half of the responses were durable for over six months, with responses seen regardless of RAS/RAF mutation status.

• Median progression-free survival (PFS) was 5.5 months, with over 41% of patients progression-free at six months.

• Disease control rate approached 87-90%, with notable rates of partial responses.